Skip to main content
. 2021 Dec 21;12:781379. doi: 10.3389/fphar.2021.781379

FIGURE 3.

FIGURE 3

Risk of acute kidney injury comparing empagliflozin with linagliptin groups in the PSM cohort and subgroups. AHR = adjusted hazard ratio by patient age, sex, baseline comorbid, laboratory results and baseline medication users; UACR = urine albumin creatinine ratio; CVD = cardiovascular disease; ACEI/ARB = angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.